A comparison of the effectiveness of biologic therapies for asthma: a systematic review and network meta-analysis

5	Authors
6	Tyler Bitre MD
7	Department of Medicine
2 2	McMaster University Hamilton ON
q	Wewaster Onversity, Hummon, ON
10	Tanvir Jaccal BSc
11	Department of Aposthosia
12	Malaster Laivenity Lamilton ON
12	wewaster University, Hamilton, UN
1/	Albi Angiali PHSa
15	Albi Angjeli, Brisc
16	Fuculty of Health Sciences
17	Welvaster Onversity, Hammon, ON
L/ 10	Marath Jambara DUCa
10	Vineeth Jarabana, BHSC
19	Faculty of Health Sciences
20 01	Queens University, Hamilton, UN
21))	
22 10	
2.5 D /I	Faculty of Health Sciences
∠4) ⊑	Wiciviaster University, Hamilton, UN
20 06	Assacha Umania DUCa
20	Ayesna Umair, BHSC
<u>/</u> / no	Faculty of Health Sciences
20	wiciviaster University, Hamilton, UN
29	Muine Hussein, DUC.
5U 51	Muizz Hussain, BHSC
51 22	Wichdel G. DeGroote School of Wiedlcine
5Z 52	Wiciviaster University, Hamilton, UN
55 54	
54 55	Gareth Leung, BHSC, MISC
55	Faculty of Medicine,
סכ דר	University of Ottawa, Ottawa, ON
57 50	
38	Sarah Kirsh, BSc
10	Department of Anestnesia
4U 4 1	Wiciviaster University, Hamilton, UN
+⊥ 4つ	
+Z 1 2	Jonnny Su, MD
+5 4 4	Department of Medicine
+4 1 C	McMaster University, Hamilton, UN
+5 16	
+0 17	Kairavi Desai, BHSC
+/ 10	Michael G. Degroote School of Medicine
+0 40	McMaster University, Hamilton, UN
49 - 0	
5U -1	Jade Coyne, MD
)⊥ _)	Department of Respirology
D∠ ∃ 2	St Mary's General Hospital, Kitchener, ON
55	
54 55	Sindu Iviohan, MD
55	Department of Respirology

56 57	St Mary's General Hospital, Kitchener, ON
58 59 60 61 62 63	Dena Zeraatkar, PhD Department of Health Research Methods, Evidence, and Impact; Department of Anesthesia McMaster University, Hamilton, ON Biomedical Informatics Harvard Medical School, Cambridge, MA
64	Corresponding author:
65	Tyler Pitre, MD
66	1280 Main Street West
67	Hamilton, ON
68	L8S 4L8
69	Tele: (905) 525-9140
70	Fax: (226) 507-2940
71	Email: tyler.pitre@medportal.ca
72	
73	Running head: Biologics for asthma
74	Disclaimers/Conflicts of interest: None

- 75 **Funding**: DZ is funded by a Banting postdoctoral fellowship.
- 76 **Data:** Data will be available on OSF upon publication.
- 77 Acknowledgements: None
- 78 Authors' Contributions: TP and DZ conceived the study. TJ, AA, VJ, SN, AU, MH, GL, SK, JS, KD, and TP
- 79 screened and extracted data. JC and SM reviewed the manuscript, provided clinical context to the
- 80 interpretation of the results. DZ and TP performed the analysis and GRADED the certainty of the
- 81 evidence. TP drafted the manuscript and all authors reviewed and provided intellectual input.
- 82 **Keywords:** asthma, biologics, systematic review, network meta-analysis
- 83 Word count: 3,606
- 84
- 85
- 86

88 Abstract

89 Background: Trials have not directly compared biologics for the treatment of asthma.

- 90 Objective: To comparative the relative efficacy of biologics in asthma.
- 91 Methods: We searched MEDLINE, EMBASE, CENTRAL, and clinicaltrials.gov from inception to May 31,
- 92 2022, for randomized trials addressing biologic therapies for asthma. Reviewers worked independently
- 93 and in duplicate to screen references, extract data, and assess risk of bias. We performed a frequentist
- 94 network meta-analysis and assessed the certainty of evidence using the GRADE approach. We present
- 95 dichotomous outcomes as absolute risk differences per 1000 patients and relative risk (RR) with 95%
- 96 confidence intervals (95% CI) and continuous outcomes as mean difference (MD) and 95% CI.
- 97 Results: We identified 64 trials, including 26,630 patients. For patients with eosinophilic asthma,
- tezepelumab (329 fewer exacerbations per 1000 [95% CI 272.6 to 366.6 fewer]) and dupilumab (319.6
- 99 fewer exacerbations per 1000 [95% Cl 272.6 to 357.2 fewer]) reduce exacerbations compared to placebo
- 100 (high certainty). Tezepelumab (MD 0.24 L [95% CI 0.16 to 0.32]) and dupilumab (0.25 L (95% CI 0.21 to
- 101 0.29) improve lung function (FEV1) compared to placebo (high certainty). Both tezepelumab (110.97
- 102 fewer hospital admissions per 1000 (95% CI 94.53 to 120.56 fewer) and dupilumab (97.27 fewer
- 103 hospitalizations [4.11 to 124.67 fewer]) probably reduce hospital admissions compared to placebo
- 104 (moderate certainty). For patients with low eosinophils, biologics probably do not improve asthma
- 105 outcomes. For these patients, tezepelumab (MD 0.1 L [95% CI 0 to 0.19]) and dupilumab (MD 0.1 L [95%
- 106 Cl 0 to 0.20)] may improve lung function (low certainty).
- 107 Conclusion: Tezepelumab and dupilumab are effective at reducing exacerbations. For patients with low
- 108 eosinophils, however, clinicians should probably be more judicious in use of biologics, including
- 109 tezepelumab since they probably do not confer substantial benefit.

110 Introduction

- 111 Asthma is a respiratory condition that affects an estimated 300 million people and is associated with
- significant morbidity¹. Patients with asthma that is inadequately controlled by high dose inhaled
- 113 corticosteroids and long-acting β2-agonists and patients who rely on oral corticosteroids may benefit
- 114 from biologics². Clinicians need to consider both disease severity and inflammatory endotype (type 2
- 115 high and type 2 low) to select optimal patients for biologic therapies.
- 116 To date, no trial has directly compared biologics for the treatment of uncontrolled asthma and the
- 117 choice of biologic has been largely guided by biological and practical considerations, such as assessing
- 118 inflammatory biomarkers (e.g., blood and sputum eosinophils, fractional exhaled nitric oxide, IgE levels)
- and access and payer coverage. Additionally, the optimal biologic for patients who qualify for more than
- 120 one option and the order in which clinicians should trial biologics for patients are unclear ³. Access to
- most biologics has been limited to patients with specific clinical phenotypes such as allergic and
- 122 nonallergic eosinophilic asthma. The emergence of anti-alarmins—treatments that should theoretically
- 123 be effective regardless of eosinophil levels—further necessitates additional evidence to help select
- 124 optimal biologics for patients ⁴.
- 125 To address these challenges, we present a systematic review and network meta-analysis comparing
- 126 biologics for severe uncontrolled asthma. A network meta-analysis pools results across two or more
- 127 studies and, unlike a traditional pairwise meta-analysis, facilitates comparisons of three or more
- 128 interventions simultaneously ⁵. A network meta-analysis can also yield more precise estimates than a
- 129 traditional pairwise meta-analysis and can facilitate comparison of interventions that have not been
- directly compared against each other. Our network meta-analysis improves on previous reviews on the
- 131 topic by including the last trial data not included in previous reviews, by considering eosinophil levels,
- and by using the GRADE guidance to interpret and contextualize findings $^{6-12}$.

133 Methods

We registered our protocol on Open Science Framework (https://osf.io/m29du/) on June 14, 2022. We
 report our results using the PRISMA-NMA extension ¹³.

136 Search strategy

- 137 In consultation with an experienced research librarian, we searched MEDLINE, EMBASE, CENTRAL, and
- clinicaltrials.gov from inception to May 31, 2022, for randomized trials addressing biologic therapies for

asthma. We did not restrict the search by language or date of publication. We supplemented our search

140 by reviewing references of similar systematic reviews ^{7 8 14-16}. eTable 1 presents our full search strategy.

141 Screening

- 142 Following training and calibration exercises to ensure sufficient agreement, pairs of reviewers, working
- 143 independently and in duplicate, reviewed titles and abstracts of search results and subsequently the full-
- 144 texts of records deemed potentially eligible at the title and abstract screening stage.
- 145 We included trials that randomized adults with asthma to one or more biologic therapies with standard
- 146 care, placebo, or other biologic therapies, regardless of language or date of publication. We included
- 147 trials that recruited both children and adults if 80% or more patients were adults (>18 years). We
- 148 excluded trials that reported on the effects of aerosolized or nebulized biologics or trials that included
- 149 fewer than 10 participants in each arm.
- 150 Reviewers resolved discrepancies by discussion, or, when necessary, by adjudication with a third party.

151 Data extraction

- 152 Following training and calibration exercises to ensure sufficient agreement, pairs of reviewers were
- assigned the same trials, and then they worked independently and in duplicate, to extract data from
- eligible studies. This was done to avoid collection error. We extracted data on trial characteristics (e.g.,
- 155 country of recruitment), patient characteristics (e.g., age, eosinophil levels), intervention characteristics
- 156 (e.g., dose and duration), and outcomes. The coreASTHMA core outcome set—a multistakeholder core
- 157 outcome set for asthma—informed our outcomes of interest ¹⁷, which include exacerbations, asthma
- 158 control as measured by the Asthma Control Questionnaire, lung function measured by
- 159 prebronchodilator forced expiratory volume in 1 second (FEV1), hospitalizations, reduction in use of
- 160 systemic corticosteroids by \geq 50%, and adverse events leading to discontinuation.
- 161 We anticipated that the effects of biologics on exacerbations, asthma control, and lung function may 162 differ according to baseline eosinophil count. To facilitate subgroup analyses, we extracted subgroup 163 data based on baseline blood and sputum eosinophil count, when reported. We classified trials as 164 reporting on eosinophilic asthma when 80% or more of patients had blood eosinophils of \geq 300 165 eosinophils per µL in the past year, \geq 150 eosinophils per µL in the trial screening period (to allow for 166 random fluctuations in blood eosinophils), or sputum eosinophils \geq 3%. These cut-offs were based on 167 common classifications found in randomized trials and broadly fits the research and clinical definitions.

168 **Risk of bias assessments**

- Following training and calibration exercises to ensure sufficient agreement, pairs of reviewers, working independently and in duplicate, assessed the risk of bias of trials using a modification of the Cochraneendorsed RoB 2.0 tool ¹⁸¹⁹. We rated each outcome as either at (1) low risk of bias, (2) probably low risk of bias, (3) probably high risk of bias or (4) high risk of bias, across the following domains: bias arising from the randomisation process; bias owing to departures from the intended intervention; bias from missing outcome data; bias in measurement of the outcome; bias in selection of the reported results. Trials were rated at high risk of bias overall if one or more domains were rated at probably high or high
- 176 risk of bias. Reviewers resolved discrepancies by discussion and, when not possible, with adjudication by
- a third party. eTable 2 presents the modified risk of bias tool.

178 Data analysis

- 179 We present the results of dichotomous outcomes as relative risks (RRs) and continuous outcomes as
- 180 mean differences (MDs), with associated 95% confidence intervals (95% Cls). To facilitate interpretation,
- 181 for dichotomous outcomes, we calculate absolute effects expressed as events per 1,000 patients, using
- 182 the median risk in the placebo arms as the assumed baseline risk without biologics.
- 183 For each outcome, we performed frequentist random-effects network meta-analysis using the restricted 184 maximum likelihood (REML) estimator. Although Bayesian methods are also available, a recent study 185 that investigated the differences between the two approaches found there are seldom important 186 differences in the results of Bayesian and frequentist approaches for network meta-analysis²⁰. We 187 categorized each biologic drug as a separate node in the network. We anticipated that the effects of 188 biologic therapies on exacerbations, asthma control, and lung function may differ based on baseline 189 eosinophil count. For these outcomes, we performed three analyses: one restricted to patients with high 190 eosinophils, one restricted to patients with low eosinophils, and one including all patients.
- 191 To test our assumption of transitivity and to determine whether there were important differences
- between trial results and trial and patient characteristics, we performed meta-regressions with FEV1,
- age, sex, blood eosinophils (mean), baseline oral corticosteroid use, duration of asthma, duration of
- 194 follow up, and year of publication as independent variables. Meta-regressions test whether one or more
- 195 independent variables influence the outcome ²¹.
- We summarize heterogeneity using the l² statistic. We considered heterogeneity ranging from 0%–40%
 as potentially unimportant, 30%–60% as moderate, 50%–90% as substantial and 75%–100% as critical ²¹.

- 198 We used the node-splitting method to test for local incoherence (difference between direct and indirect
- 199 evidence in closed loops)²². For analyses with 10 or more trials, we assessed for publication bias using
- 200 comparison-adjusted funnel plots and the Egger's test ²³.
- 201 We performed meta-analyses using meta and netmeta packages in R v. 4.1.2 (Vienna, Austria) and we
- used the networkplot command in Stata v.17 (StataCorp) to generate network plots ²⁴⁻²⁶.
- 203 Evaluation of the certainty (quality) of evidence

Reviewers, working independently and in duplicate, assessed the certainty (quality) of evidence using
 the GRADE approach for network meta-analysis ²⁷⁻²⁹. Reviewers resolved discrepancies by discussion or
 by adjudication by a third reviewer.

207 For each comparison and for each outcome, we rated the certainty of evidence as either high, 208 moderate, low, or very low based on considerations of risk of bias (i.e., study limitations), inconsistency 209 (i.e., heterogeneity in trial results), indirectness (i.e., differences between the questions addressed in 210 trials and the question of interest), publication bias (i.e., the tendency for trials with statistically 211 significant results or positive results to be published, published faster, or published in journals with 212 higher visibility), intransitivity (i.e., differences in trial characteristics across the network), incoherence 213 (i.e., difference between direct and indirect effects), and imprecision (i.e., random error). High certainty 214 evidence indicates situations in which we are confident that the estimated effect represents the true 215 effect, and low or very low certainty evidence indicates situations in which the estimated effect may be 216 substantially different from the true effect. We made judgements about imprecision using the minimally contextualized GRADE approach ²⁹. This 217

218 approach does not consider statistical significance as the only indicator of whether an intervention is 219 effective. An estimate may not be statistically significant but may still have evidence of moderate 220 certainty for benefit or harm, depending on the width of the confidence intervals and whether they 221 cross the thresholds of clinical significance. Conversely, an intervention may produce results that are 222 statistically significant but that indicate no important benefit or harm (e.g., a 10 mL change in FEV1). A 223 minimally contextualized approach considers whether confidence intervals include the minimally 224 important difference (the smallest change in the outcome considered to be important to patients) and 225 does not consider whether it includes both minimally important and large effects.

We sourced minimally important differences from the literature or by consensus of the authors. We considered a 20% reduction in risk of exacerbations ^{30 31}, 0.5 reduction in the Asthma Control

- 228 Questionnaire ³¹, 100 mL reduction in FEV1 ^{30 32}, 5% reduction in risk of hospital admissions, 20%
- increase in risk of reducing oral corticosteroids by ≥50%, and a 10% increase in risk of adverse events
- 230 leading to discontinuation to be minimally important.
- 231 We report our results using guidance from the GRADE Working Group, which involves describing the
- effect of an intervention based on the certainty of evidence (i.e., high certainty evidence the drug is
- 233 effective, moderate certainty evidence the drug is probably effective, low certainty evidence the drug
- may be effective and very low certainty evidence the effect of the drug is unclear)³³.
- 235 We assessed the credibility of meta-regressions using the ICEMAN tool ³⁴.
- 236 Results

237 Search results

- 238 Our search yielded 3,225 unique references. We identified a total of 58 eligible publications reporting on
- 239 64 unique trials (i.e., some publications reported on more than one trial) with 26,630 patients ^{10-12 35-88}.
- 240 Four trials were included in the systematic review but did not report on outcomes to be included in the
- 241 meta-analysis ^{38 55 64 69}. All trials were published in peer-reviewed journals in English. eFigure 1 presents
- additional details related to study selection.

243 Trial and participant characteristics

- Table 1 presents trial and participant characteristics. Nineteen trials (4,974) reported on omalizumab,
- eight (4,511 patients) on fevipiprant, seven (2,511 patients) on reslizumab, six (1,966 patients) on
- 246 mepolizumab, four (2,312 patients) on tralokinumab, four (1,799 patients) on tezepelumab, three (1,090
- patients) on dupilumab, eight (4,043 patients) on benralizumab, one (502 patients) on astegolimab, and
- one (296 patients) on itepekimab ^{10-12 35-88}. We included two additional studies that reported on
- subgroups for omalizumab and eosinophils ^{89 90}.
- Trials typically recruited adult patients with moderate to severe asthma on medium to high dose inhaled corticosteroids and other controller medications and with a history of one or more exacerbations in the previous year that required a short course of prednisone or hospitalization. Only five trials reported on mild patients, three of which also included moderate patients. Patients were also generally required to be symptomatic, as assessed by the Asthma Control Questionnaire.
- Fifteen trials (5,791 patients) recruited patients with high eosinophils (blood eosinophils of ≥300
- eosinophils per μ L in the past year, \geq 150 eosinophils per μ L in the trial screening period, or sputum
- eosinophils \geq 3%) and 51 trials (22,432 patients) recruited patients with both low and high eosinophils.

- Among trials that recruited patients with both low and high eosinophils, 19 (13,592 patients) reported subgroup analyses based on eosinophil levels for one or more of our outcomes of interest.
- 260 Out of the trials included in the pooled-analyses (60 trials), 55 (91.7%) included patients ranging from
- 261 *moderate-to-severe and five trials (8.3%) included patients with mild-to-moderate asthma* ^{45 47 57 72 76}.
- 262 Of these five trials, two reported on omalizumab, and one each for mepolizumab, benralizumab, and
- 263 fevipiprant. Risk of bias
- eTable 3 presents risk of bias assessments. We judged two trials to be at high risk of bias due to their
- 265 open-label design and inadequate description of allocation concealment ^{40 83}. We judged all other
- 266 outcomes to be at low risk of bias ^{10 11 35-39 41-82 84-87}. Pharmaceutical companies funded all trials ^{10 11 35-87}.

267 *Exacerbations*

- 268 Forty-two trials, including 20,964 patients, reported exacerbations 10-12 35-37 39 40 42 44 45 48-51 56 59-62 65 67 68 71 73-
- 269 ^{75 77 79 80 82-87}. Of these, thirty trials reported on 11,329 patients with high eosinophils ^{10-12 35 36 39 42 44 49-51 56}
- 270 ^{59 61 62 67 74 75 77 79 85-90} and fifteen trials reported 5,137 patients with low eosinophils^{10-12 35 44 49 61 74 75 85 87}.
- 271 Figure 1 presents the geometry of the networks and figure 2 presents the network forest plot.
- 272 For patients with eosinophilic asthma (>=300 cells/uL), we found moderate to high certainty evidence
- that benralizumab (RR 0.51 [95% Cl 0.41 to 0.63]), dupilumab (RR 0.32 [95% 0.24 to 0.42,]) mepolizumab
- 274 (RR 0.52 [95% Cl 0.43 to 0.64]), reslizumab (RR 0.51 [95% Cl 0.4 to 0.65]), omalizumab (RR 0.52 [0.37 to
- 0.72]) and tezepelumab (RR 0.3 [0.22 to 0.43]) probably reduce exacerbations compared to placebo.
- 276 While dupilumab and tezepelumab appear superior to the other biologics, the difference does not reach
- the minimally important difference.
- 278 For patients with low eosinophils (< 300 cells/uL), we did not find moderate or high certainty evidence
- that any of the drugs reduce exacerbations (i.e., none met the pre-specified minimally important
- difference of 20%).
- For all patients, omalizumab, astegolimab, and tralokinumab probably do not reduce exacerbations ascompared to placebo.
- Table 2 presents the summary of findings and eTables 4-6 presents all comparisons. eFigure 2-13
- 284 present the forest plots, funnel plot and network diagrams.
- eFigures 2-13 present the forest plots, funnel plot and network diagrams.

286 Asthma control (Asthma Control Questionnaire)

- 287 Thirty-six trials, including 12,161 patients, reported on asthma control using the asthma control
- 288 questionnaire ^{10-12 36 39 42 45 46 49-51 54 56-59 61 62 66 72 73 76-79 81 82 84-86 91 92}. Of these, ten trials reported on 8,212
- 289 patients with high eosinophils ^{10 11 76 77 79 81 85 86} and eight trials reported on 1,905 patients with low
- 290 eosinophils ^{10-12 49 54 61 76 85}
- 291 For patients with eosinophilic asthma, we found low certainty evidence that dupilumab may improve
- asthma control compared to placebo (MD -0.73 [95% CI -0.98 to -0.48]). We did not find moderate or
- high certainty evidence that any of the biologics improve asthma control for this population.
- 294 For patients with low eosinophils, we found moderate to high certainty evidence that benralizumab (MD
- 295 -0.23 [95% CI -0.41 to -0.06]), dupilumab (MD -0.2 [95% -0.42 to 0.02]), reslizumab (MD 0.12 [95% CI -
- 296 0.09 to 0.33]), and tezepelumab (MD -0.23 [95% Cl -0.36 to -0.09]) probably do not improve asthma
- 297 control compared to placebo.
- Table 2 presents the summary of findings and eTables 7-9 presents all comparisons. eFigure 14-25
- 299 present the forest plots, funnel plot and network diagrams.

300 Lung function (FEV1)

- 301 Forty-two trials, including 17,965 patients, reported lung function ^{10 11 35 36 39 41 42 44-47 49-51 54 56 58 59 61-63 65 66}
- 302 ^{74 75 77-80 82-85 87}. Of these, twenty-nine trials reported on 9,242 patients with high eosinophils ^{59 62 66 77 79}
- 303 and twelve trials reported on 2745 patients with low eosinophils^{10 11 58 61 75 85}.
- 304 For patients with high eosinophils, we found moderate to high certainty evidence that dupilumab (MD
- 305 0.25 L [95% CI 0.21 to 0.29]), reslizumab (MD 0.19 L [95% CI 0.12 to 0.25]), and tezepelumab (MD 0.24 L
- 306 [0.16 to 0.32]) probably improve lung function compared to placebo. We found moderate certainty
- evidence that dupilumab is probably superior to benralizumab (MD 0.11 L [95% Cl 0.05 to 0.16]) and
- mepolizumab (MD 0.15 L [95% CI 0.08 to 0.22]) for improving lung function and that tezepelumab is
- probably superior to mepolizumab (MD 0.15 L [95% Cl 0.05 to 0.24]). We found moderate certainty
- evidence that dupilumab and tezepelumab probably improve lung function equally well (MD 0.01 L [95%
- 311 CI -0.08 to 0.1]).
- For patients with low eosinophils, we did not find moderate or high certainty evidence that any biologics
- improve lung function.

- Table 2 presents the summary of findings and eTables 10-12 presents all comparisons. eFigures 26-37
- 315 present the forest plots, funnel plot and network diagrams.

316 Hospital admissions

- Thirteen trials, including 3,113 patients, reported on hospital admission ^{10 11 35 40 45 48 49 62 67 71 82 85}
- We found moderate certainty evidence that mepolizumab (RR 0.29 [95% CI 0.09 to 0.97]), omalizumab
- 319 (RR 0.38 [95% CI 0.23 to 0.65]), and tezepelumab (RR 0.19 [95% CI [0.12 to 0.31]) probably reduce
- 320 hospital admissions compared to placebo.
- 321 We found moderate to high certainty evidence that omalizumab is probably superior to benralizumab
- 322 (RR 0.44 [95% CI 0.25 to 0.78]) and tralokinumab (RR 0.5 [95% CI 0.27 to 0.95]) for reducing hospital
- admissions. We found moderate certainty evidence that tezepelumab is probably superior to
- benralizumab for reducing hospitalizations (RR 0.22 [95% Cl 0.13 to 0.37]).
- Table 2 presents the summary of findings and eTable 13 presents all comparisons. eFigures 38-41
- 326 present the forest plots, funnel plot and network diagram.
- 327 Reduction in use of oral corticosteroids (\geq 50% reduction in oral corticosteroids)
- Six trials, including 4849 patients, reported \geq 50% reduction in oral corticosteroids ^{12 39 44 48 75 86}.
- We found moderate certainty evidence that benralizumab (RR 1.77 [95% Cl 1.29 to 2.43]), dupilumab
- 330 (RR 1.49 [95% Cl 1.22 to 1.83], and mepolizumab [RR 1.61 [95% Cl 1.07 to 2.41]) probably reduce use of
- oral corticosteroids compared to placebo. We did not find moderate or high certainty evidence that
- either of these drugs are superior to each other.
- Table 2 presents the summary of findings and eTable 14 presents all comparisons. eFigures 42-45
- 334 present the forest plots, funnel plot and network diagrams.

335 Adverse events leading to discontinuation

- Forty-seven trials, including 8,781 patients, reported adverse events leading to discontinuation ^{10-12 35-37}
- **3**9-41 43-46 48-52 54 56 60-63 65 67 68 70-73 75-80 82-87.
- We have moderate to high certainty evidence that benralizumab (RR 1.65 [95% Cl 0.79 to 3.45]),
- dupilumab (RR 1.03 [95% Cl 0.46 to 2.3]), fevipiprant (RR 1.01 [95% Cl 0.65 to 1.57]), mepolizumab [RR
- 340 0.65 [95% CI 0.36 to 1.16]), omalizumab (RR 1.2 [95% CI 0.80 to 1.81]), reslizumab (RR 0.65 [0.41 to

- 1.02]), tezepelumab (RR 0.68 [95% CI 0.0.34 to 1.35]), and tralokinumab (RR 2.7 [95% CI 1.45 to 5])
- 342 probably do not increase the risk adverse events compared to placebo.
- Table 2 presents the summary of findings and eTable 15 presents all comparisons. eFigures 46-49
- 344 present the forest plots, funnel plot and network diagrams.

345 *Meta-regressions and sensitivity analyses*

- 346 We did not find credible effect modification based on year of the trial publication, age, sex, duration of
- 347 asthma, duration of follow-up, year of publication, and disease severity (assessed based on baseline
- 348 FEV1 and oral corticosteroid use). eTable 16 presents the results of this analysis.
- 349 When excluding mild-to-moderate trials from the pooled analyses, there was no difference in the overall
- effect on any outcomes. eFigure 50-58 presents the forest plots for the sensitivity analyses.

351 Discussion

352 Main findings

- 353 Our systematic review and network meta-analysis presents data from 63 trials addressing the
- effectiveness and safety of biologics for uncontrolled severe asthma. We show that for patients with
- eosinophilic asthma, tezepelumab and dupilumab are the most effective at reducing asthma
- exacerbations and improving lung function. Furthermore, we found that tezepelumab and dupiliumab
- are probably better at improving lung function than other available biologic treatments. We did not find
- 358 moderate or high certainty evidence that either of these drugs are superior to each other.
- 359 Contrary to expectations, for patients with low eosinophils, biologics, including tezepelumab that has
- been marketed as effective even in patients with low eosinophils ⁹³, probably do not prevent
- 361 exacerbations or improve asthma control or lung function.
- 362 While our findings may appear to deviate from previously published trials, this is not surprising ¹⁰⁻¹². In
- interpreting the results, we use latest GRADE guidance and consider both the magnitude of effect and
- the certainty (quality) of evidence. We also consider effects in relation to the minimally important
- 365 difference for each outcome, while trials generally interpret results based on statistical significance.
- 366 Results from network meta-analyses may also be less precise than those reported in trials since the
- 367 network estimate incorporates network wide heterogeneity ²¹.
- Considering these factors, while our findings may seem incongruent with the interpretation of previous
 trials, they are not incongruent with previously published trial results. The SOURCE trial, for example, did

not find evidence that tezepelumab reduces oral corticosteroids or exacerbations in patients with low
 eosinophils and the effect of tezepelumab on lung function in patients with high eosinophils was twice
 that of patients with low eosinophils ¹². Similarly, NAVIGATOR found the effect of tezepelumab on lung

function to be much greater in patients with high eosinophils than low eosinophils¹¹.

374 Strengths and limitation

- 375 The strengths of this review include our comprehensive search for trials addressing biologics for asthma,
- 376 duplicate screening and data extraction, and rigorous evaluation of the certainty (quality) of evidence.
- 377 We considered the potential differential effects of biologics based on eosinophil counts, which play a
- key role in the pathogenesis of severe asthma. We focused on patient-important outcomes and our
- 379 choice of outcomes was guided by a core outcome set developed by stakeholders including patients ¹⁷.
- 380 We apply rigorous methods for assessing the certainty of evidence from network meta-analyses using a
- 381 minimally contextualized approach and minimally important differences ²⁹. Furthermore, we considered
- the comparability of trials by performing meta-regression, demonstrating that there was no appreciable
- difference that would obviate the assumption of transitivity.
- 384 Although we performed a rigorous search for eligible studies and supplemented our search with
- 385 previous systematic reviews of biologics for asthma, it is possible that we missed eligible trials.

386 While the GRADE framework presents a transparent system for assessing the certainty of evidence and 387 accounts for all factors that may bear on the certainty of evidence, its application is subjective and 388 others rating the certainty of evidence may come to different conclusions. Further, our assessment of 389 the certainty of evidence using the minimally contextualized approach required us to identify the 390 minimally important difference. We encourage evidence users to consider effects that their patients 391 would consider to be important when interpreting our results. For example, some patients may place a 392 high value on reductions in exacerbations and may consider a reduction in exacerbations less than 20% 393 to still be important.

In our network meta-analysis, we categorized different doses of the same biologic and different routes of administration (i.e., subcutaneous vs. intravenous) in the same node. While this approach maximized the number of patients included in each node, the effects of biologics may vary by dose and route of administration. Most trials, however, that tested different doses and routes of administration did not find evidence of clinically important differences in effects ^{10 61}. 399 Clinicians may be concerned that the included trials were not sufficiently similar to justify pooling. 400 Although we detected moderate-to-substantial level network heterogeneity in some of the outcomes, 401 we took this into account when providing GRADE ratings. For most part, the degree of heterogeneity did 402 not warrant rating down the certainty and differences in the studies did not have appreciable effect on 403 the results. The overwhelming majority of studies reported on moderate to severe asthma and only a 404 few trials reported on patients with mild asthma. We performed meta-regressions testing for potential 405 effect modification based on trial characteristics (e.g., year of publication) and patient characteristics (e.g., severity, duration of asthma) and did not find evidence that the effects of biologics varied based 406 407 on these factors. Although there was a statistically significant effect with age and sex in the dupiliumab 408 trials, this was not seen in other comparisons and likely resulting from chance. Using the ICEMAN tool, 409 we found the credibility of this subgroup to be very low.

410 Trials reported data on the effects of biologics between 12 and 52 weeks. The effects of biologics,

411 including potential adverse events, beyond these timeframes are uncertain.

412 We detected possible evidence of publication bias in overall networks for exacerbations, ACQ and FEV1,

413 but not in the subgroups. It is possible we were underpowered to detect publication bias in the

414 subgroup networks.

415 We report data on adverse events that led to discontinuation. While we found biologics to be well

tolerated, serious and life-threatening adverse events are possible and were not captured by our review.

417 A very small proportion of patients, for example, may experience anaphylaxis—typically after the first

418 three doses.

419 We present convincing evidence that the effects of biologics vary based on eosinophils. We show that

420 biologics, including tezepelumab, are probably not effective for patients with low eosinophils—a finding

that is consistent with a previous review and previously published trials, although not explicitly

422 emphasized in the review or trials ¹¹¹²¹⁶. Patients' eosinophils also inherently vary over time. It is

423 possible that trials may capture patients at a random high or low in eosinophil count as many trials

recruiting patients with raised blood eosinophils usually obtain a single time point result of greater than

425 150-300 cells/uL. Furthermore, trials varied in their cut offs for "high eosinophils", while most reported

426 >=300 cells/uL, some trials included thresholds higher than 500 cells/uL. Therefore, our review may

427 underestimate differences in effects of biologics based on eosinophils.

Our review focuses on adults and includes limited data on the effects of biologics in children. Given the
 effectiveness of these drugs in adults with eosinophilic asthma, additional clinical trials in children are
 warranted. Currently, omalizumab—which we found to not be effective—is the only biologic approved

431 by the FDA for children under 6 years ⁹⁴.

432 Implications

Our results have implications for the management of patients with severe uncontrolled asthma. Our
 results support the use of biologics for the treatment of patients with high eosinophils. For patients with
 eosinophilic asthma, tezepelumab and dupilumab are effective at reducing exacerbations, without
 important differences between the two biologics.

437 Our results, however, suggest that clinicians should be more cautious using biologics for patients with

438 low eosinophils. In December 2021, the FDA approved tezepelumab for patients with severe

439 uncontrolled asthma, regardless of eosinophil levels ⁹³. Tezepelumab is regarded as the first biologic to

reduce asthma exacerbations consistently and significantly in a broad population of asthma patients. For

441 patients with low eosinophils, tezepelumab, however, did now show evidence of effectiveness. Other

investigators have also been skeptical of the effects of tezepelumab in patients with low eosinophils ⁹⁵.

443 Suboptimal response in patients with low eosinophils may be related to several pathways leading to

444 asthma, including non-eosinophilic inflammation, airflow obstruction related to airway remodeling,

significant airways hyperresponsiveness and/or mucus plugging being driven by non-eosinophil derived

446 cytokines.

447 Our results suggest that clinicians should be mindful when using tezepelumab in patients with low

eosinophils given the costs and practical issues associated with the drug (i.e., subcutaneous injection)

and since these patients are unlikely to derive as substantial of a benefit as patients with eosinophilic

450 asthma. However, for patients who have moderate-to-severe non-eosinophilic asthma, there are

451 currently few options. Clinicians may consider a short trial of anti-alarmin therapy in patients who may

452 benefit and evaluate for response in select patients.

453 Our results also do not support the use of omalizumab, which was markedly less effective than other454 biologics.

455 Conclusion

456 For patients with eosinophilic asthma, all available biologics are effective at reducing exacerbations,

457 without important differences in the effects of these biologics. Tezepelumab and dupiliumab probably

- 458 improve lung function as compared to other available treatments. For patients with low eosinophils,
- 459 however, clinicians should probably be more judicious in use of biologics, including tezepelumab, since
- they probably do not confer substantial benefit.

461

462 References

- 463 Global Asthma Global Asthma Network Global Asthma 1. Network. Report 2018 464 www.globalasthmareport.org/ Date last updated: January 2018. Date last accessed: January 17, 465 2020.
- 466 2. Global Initiative for Asthma. (2002). Global strategy for asthma management and prevention.
 467 Bethesda, Md.: National Institutes of Health, National Heart, Lung, and Blood Institute.
- 4683. Mauer Y, Taliercio RM. Managing adult asthma: The 2019 GINA guidelines. Cleve Clin J Med4692020;87(9):569-75. doi: 10.3949/ccjm.87a.19136 [published Online First: 20200831]
- 470 4. Porsbjerg CM, Sverrild A, Lloyd CM, Menzies-Gow AN, Bel EH. Anti-alarmins in asthma: targeting the 471 airway epithelium with next-generation biologics. *European Respiratory Journal* 2020;56(5)
- 5. Sadeghirad B, Foroutan F, Zoratti MJ, Busse JW, Brignardello-Petersen R, Guyatt G, et al. Theory and
 practice of Bayesian and frequentist frameworks for network meta-analysis. *BMJ Evid Based Med* 2022 doi: 10.1136/bmjebm-2022-111928 [published Online First: 20220627]
- 475 6. Ando K, Fukuda Y, Tanaka A, Sagara H. Comparative Efficacy and Safety of Tezepelumab and Other
 476 Biologics in Patients with Inadequately Controlled Asthma According to Thresholds of Type 2
 477 Inflammatory Biomarkers: A Systematic Review and Network Meta-Analysis. *Cells* 2022;11(5)
 478 doi: 10.3390/cells11050819 [published Online First: 20220226]
- 479 7. Edris A, Lahousse L. Monoclonal antibodies in type 2 asthma: an updated network meta-analysis.
 480 *Minerva Med* 2021;112(5):573-81. doi: 10.23736/s0026-4806.21.07623-0 [published Online
 481 First: 20210514]
- 482 8. Edris A, De Feyter S, Maes T, Joos G, Lahousse L. Monoclonal antibodies in type 2 asthma: a
 483 systematic review and network meta-analysis. *Respir Res* 2019;20(1):179. doi: 10.1186/s12931484 019-1138-3 [published Online First: 20190808]
- 485 9. Ramonell RP, Iftikhar IH. Effect of Anti-IL5, Anti-IL5R, Anti-IL13 Therapy on Asthma Exacerbations: A
 486 Network Meta-analysis. *Lung* 2020;198(1):95-103. doi: 10.1007/s00408-019-00310-8 [published
 487 Online First: 20200101]
- 48810. Corren J, Parnes JR, Wang L, Mo M, Roseti SL, Griffiths JM, et al. Tezepelumab in Adults with489Uncontrolled Asthma. N Engl J Med 2017;377(10):936-46. doi: 10.1056/NEJMoa1704064
- 490 11. Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME, et al. Tezepelumab in Adults
 491 and Adolescents with Severe, Uncontrolled Asthma. N Engl J Med 2021;384(19):1800. doi:
 492 https://doi.org/10.1056/NEJMoa2034975
- 493 12. Wechsler ME, Menzies-Gow A, Brightling CE, Kuna P, Korn S, Welte T, et al. Evaluation of the oral 494 corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent 495 asthma (SOURCE): a randomised, placebo-controlled, phase 3 study. *Lancet respiratory medicine* 496 2022 doi: <u>https://doi.org/10.1016/S2213-2600(21)00537-3</u>
- Hutton B, Catalá-López F, Moher D. [The PRISMA statement extension for systematic reviews
 incorporating network meta-analysis: PRISMA-NMA]. *Med Clin (Barc)* 2016;147(6):262-6. doi:
 10.1016/j.medcli.2016.02.025 [published Online First: 20160331]
- 14. Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children.
 Cochrane Database Syst Rev 2014(1):Cd003559. doi: 10.1002/14651858.CD003559.pub4
 [published Online First: 20140113]
- 503 15. Farne HA, Wilson A, Powell C, Bax L, Milan SJ. Anti-IL5 therapies for asthma. *Cochrane Database Syst* 504 *Rev* 2017;9(9):Cd010834. doi: 10.1002/14651858.CD010834.pub3 [published Online First:
 505 20170921]
- 50616. Menzies-Gow A, Steenkamp J, Singh S, Erhardt W, Rowell J, Rane P, et al. Tezepelumab compared507with other biologics for the treatment of severe asthma: a systematic review and indirect508treatment comparison. J Med Econ 2022;25(1):679-90. doi: 10.1080/13696998.2022.2074195

- 17. Tejwani V, Chang HY, Tran AP, Naber JA, Gutzwiller FS, Winders TA, et al. A multistakeholder Delphi
 consensus core outcome set for clinical trials in moderate-to-severe asthma (coreASTHMA). Ann
 Allergy Asthma Immunol 2021;127(1):116-22.e7. doi: 10.1016/j.anai.2021.03.022 [published
 Online First: 20210327]
- 18. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for
 assessing risk of bias in randomised trials. *Bmj* 2019;366:I4898. doi: 10.1136/bmj.I4898
 [published Online First: 20190828]
- Pitre T, Van Alstine R, Chick G, Leung G, Mikhail D, Cusano E, et al. Antiviral drug treatment for
 nonsevere COVID-19: a systematic review and network meta-analysis. *Cmaj* 2022;194(28):E969 e80. doi: 10.1503/cmaj.220471
- Sadeghirad B, Foroutan F, Zoratti MJ, Busse JW, Brignardello-Petersen R, Guyatt G, et al. Theory and
 practice of Bayesian and frequentist frameworks for network meta-analysis. *BMJ Evidence- Based Medicine* 2022:bmjebm-2022-111928. doi: 10.1136/bmjebm-2022-111928
- 52221. Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted523systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of524Interventions. Cochrane Database Syst Rev 2019;10:Ed000142.52510.1002/14651858.Ed000142
- van Valkenhoef G, Dias S, Ades AE, Welton NJ. Automated generation of node-splitting models for
 assessment of inconsistency in network meta-analysis. *Res Synth Methods* 2016;7(1):80-93. doi:
 10.1002/jrsm.1167 [published Online First: 20151013]
- 529 23. Chaimani A, Salanti G. Using network meta-analysis to evaluate the existence of small-study effects
 530 in a network of interventions. *Res Synth Methods* 2012;3(2):161-76. doi: 10.1002/jrsm.57
 531 [published Online First: 20120601]
- 532 24. Rücker G, Schwarzer G, Krahn U, König J, Schwarzer MG. Package 'netmeta'. Network Meta-Analysis
 533 using Frequentist Methods (Version 07-0) 2015
- 534 25. Schwarzer G. meta: An R package for meta-analysis. *R news* 2007;7(3):40-45.
- 53526. Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-536analysis in STATA. PloS one 2013;8(10):e76654.
- 537 27. Brignardello-Petersen R, Bonner A, Alexander PE, Siemieniuk RA, Furukawa TA, Rochwerg B, et al.
 538 Advances in the GRADE approach to rate the certainty in estimates from a network meta 539 analysis. J Clin Epidemiol 2018;93:36-44. doi: 10.1016/j.jclinepi.2017.10.005 [published Online
 540 First: 20171017]
- 54128. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging542consensus on rating quality of evidence and strength of recommendations. *Bmj*5432008;336(7650):924-6. doi: 10.1136/bmj.39489.470347.AD
- 544 29. Brignardello-Petersen R, Florez ID, Izcovich A, Santesso N, Hazlewood G, Alhazanni W, et al. GRADE
 545 approach to drawing conclusions from a network meta-analysis using a minimally contextualised
 546 framework. *Bmj* 2020;371:m3900. doi: 10.1136/bmj.m3900 [published Online First: 20201111]
- 30. Rogliani P, Calzetta L. Clinical Interpretation of Efficacy Outcomes in Pharmacological Studies on
 Triple Fixed-Dose Combination Therapy for Uncontrolled Asthma: Assessment of IRIDIUM and
 ARGON Studies. J Exp Pharmacol 2022;14:1-5. doi: 10.2147/jep.S336304 [published Online First:
 20220111]
- 55131. Bonini M, Di Paolo M, Bagnasco D, Baiardini I, Braido F, Caminati M, et al. Minimal clinically552important difference for asthma endpoints: an expert consensus report. Eur Respir Rev5532020;29(156) doi: 10.1183/16000617.0137-2019 [published Online First: 20200603]
- 55432. Tepper RS, Wise RS, Covar R, Irvin CG, Kercsmar CM, Kraft M, et al. Asthma outcomes: pulmonary555physiology. J Allergy Clin Immunol 2012;129(3 Suppl):S65-87. doi: 10.1016/j.jaci.2011.12.986

33. Santesso N, Glenton C, Dahm P, Garner P, Akl EA, Alper B, et al. GRADE guidelines 26: informative
 statements to communicate the findings of systematic reviews of interventions. *J Clin Epidemiol* 2020;119:126-35. doi: 10.1016/j.jclinepi.2019.10.014 [published Online First: 20191109]

- 55934. Schandelmaier S, Briel M, Varadhan R, Schmid CH, Devasenapathy N, Hayward RA, et al.560Development of the Instrument to assess the Credibility of Effect Modification Analyses561(ICEMAN) in randomized controlled trials and meta-analyses. Cmaj 2020;192(32):E901-e06. doi:56210.1503/cmaj.200077
- 35. Panettieri RA, Sjobring U, Peterffy A, Wessman P, Bowen K, Piper E, et al. Tralokinumab for severe,
 uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo controlled, phase 3 clinical trials. *Lancet respiratory medicine* 2018;6(7):511. doi:
 https://doi.org/10.1016/S2213-2600(18)30184-X
- 56736. Brightling CE, Gaga M, Inoue H, Li J, Maspero J, Wenzel S, et al. Effectiveness of fevipiprant in
reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3
randomised controlled trials. Lancet respiratory medicine 2021;9(1):43. doi:
https://doi.org/10.1016/S2213-2600(20)30412-4
- 37. Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M, et al. Efficacy and tolerability
 of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma
 and persistent allergic rhinitis: SOLAR. *Allergy* 2004;59(7):709. doi:
 <u>https://doi.org/10.1111/j.1398-9995.2004.00550.x</u>
- 38. Gevaert P, Bachert C, Maspero JF, Cuevas M, Steele D, Acharya S, et al. Phase 3b randomized
 controlled trial of fevipiprant in patients with nasal polyposis with asthma (THUNDER). *Journal* of Allergy and Clinical Immunology 2022 doi: <u>https://doi.org/10.1016/j.jaci.2021.12.759</u>
- 39. Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, et al. Oral Glucocorticoid-Sparing Effect of
 Benralizumab in Severe Asthma. *New England journal of medicine* 2017;376(25):2448. doi:
 <u>https://doi.org/10.1056/NEJMoa1703501</u>
- 58140. Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-
immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-
severe) allergic asthma. Allergy 2004;59(7):701. doi: <a href="https://doi.org/10.1111/j.1398-5849995.2004.00533.x
- 41. Bardelas J, Figliomeni M, Kianifard F, Meng X. A 26-week, randomized, double-blind, placebocontrolled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma. *Journal of asthma* 2012;49(2):144. doi: https://doi.org/10.3109/02770903.2011.648296
- 589 42. Harrison TW, Chanez P, Menzella F, Canonica GW, Louis R, Cosio BG, et al. Onset of effect and impact 590 on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms 591 for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, 592 controlled, phase 3b trial. Lancet respiratory medicine 2021;9(3):260. doi: 593 https://doi.org/10.1016/S2213-2600(20)30414-8
- 59443. Bateman ED, Guerreros AG, Brockhaus F, Holzhauer B, Pethe A, Kay RA, et al. Fevipiprant, an oral
prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose
inhaled corticosteroids. The european respiratory journal 2017;50(2) doi:

 https://doi.org/10.1183/13993003.00670-2017
- 44. Bernstein JA, Virchow JC, Murphy K, Maspero JF, Jacobs J, Adir Y, et al. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials. *Lancet respiratory medicine* 2020;8(5):461. doi: https://doi.org/10.1016/S2213-2600(19)30372-8

- 60345. Ferguson GT, FitzGerald JM, Bleecker ER, Laviolette M, Bernstein D, LaForce C, et al. Benralizumab604for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind,605placebo-controlled, phase 3 trial. Lancet respiratory medicine 2017;5(7):568. doi:606https://doi.org/10.1016/S2213-2600(17)30190-X
- 46. Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for Inadequately
 Controlled Asthma With Elevated Blood Eosinophil Levels: a Randomized Phase 3 Study. *Chest* 2016;150(4):789. doi: https://doi.org/10.1016/j.chest.2016.03.032
- 47. Boulet LP, Chapman KR, ocirc, eacute, Kalra S, Bhagat R, et al. Inhibitory effects of an anti-IgE
 antibody E25 on allergen-induced early asthmatic response. *American journal of respiratory and critical care medicine* 1997;155(6):1835. doi: <u>https://doi.org/10.1164/ajrccm.155.6.9196083</u>
- 61348. Busse WW. Anti-immunoglobulin E (omalizumab) therapy in allergic asthma. American Journal of614Respiratory and Critical Care Medicine 2001;164(8 II):S12-S17. doi:615http://dx.doi.org/10.1164/ajrccm.164.supplement_1.2103026
- 49. FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, et al. Benralizumab, an antiinterleukin-5 receptor & agr; monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet* 2016;388(10056):2128. doi: <u>https://doi.org/10.1016/S0140-6736(16)31322-</u>
 8
- 50. Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, et al. Reslizumab for
 inadequately controlled asthma with elevated blood eosinophil counts: results from two
 multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet
 respiratory medicine 2015;3(5):355. doi: https://doi.org/10.1016/S2213-2600(15)00042-9
- 51. Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, et al. Reslizumab for poorly controlled,
 eosinophilic asthma: a randomized, placebo-controlled study. *American journal of respiratory and critical care medicine* 2011;184(10):1125. doi: https://doi.org/10.1164/rccm.201103-03960C
- 52. Chanez P, Contin-Bordes C, Garcia G, Verkindre C, Didier A, De Blay F, et al. Omalizumab-induced
 decrease of FcepsilonRI expression in patients with severe allergic asthma. *Respiratory Medicine* 2010;104(11):1608-17. doi: http://dx.doi.org/10.1016/j.rmed.2010.07.011
- 53. Corren J, Wood RA, Patel D, Zhu J, Yegin A, Dhillon G, et al. Effects of omalizumab on changes in pulmonary function induced by controlled cat room challenge. *Journal of allergy and clinical immunology* 2011;127(2):398. doi: <u>https://doi.org/10.1016/j.jaci.2010.09.043</u>
- 54. Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 Study of Reslizumab in Patients With
 Poorly Controlled Asthma: effects Across a Broad Range of Eosinophil Counts. *Chest* 2016;150(4):799. doi: <u>https://doi.org/10.1016/j.chest.2016.03.018</u>
- 55. Djukanovic R, Wilson SJ, Kraft M, Jarjour N, Steel M, Chung KF, et al. Effect of treatment with anti-IgE
 antibody (Omalizumab) on airway inflammation in mild atopic asthma. American thoracic
 society 99th international conference 2003:C082.
- 56. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe
 eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. *Lancet*(*london, england*) 2012;380(9842):651. doi: https://doi.org/10.1016/S0140-6736(12)60988-X
- 57. Erpenbeck VJ, Popov TA, Miller D, Weinstein SF, Spector S, Magnusson B, et al. The oral CRTh2
 antagonist QAW039 (fevipiprant): a phase II study in uncontrolled allergic asthma. *Pulmonary pharmacology & therapeutics* 2016;39:54. doi: <u>https://doi.org/10.1016/j.pupt.2016.06.005</u>
- 64758. Wechsler ME, Ruddy MK, Pavord ID, Israel E, Rabe KF, Ford LB, et al. Efficacy and Safety of648Itepekimab in Patients with Moderate-to-Severe Asthma. New England journal of medicine6492021;385(18):1656. doi: https://doi.org/10.1056/NEJMoa2024257

- 650 59. Panettieri RA, Welte T, Shenoy KV, Korn S, Jandl M, Kerwin EM, et al. Onset of effect, changes in 651 airflow obstruction and lung volume, and health-related quality of life improvements with 652 benralizumab for patients with severe eosinophilic asthma: phase iiib randomized, controlled 653 trial (SOLANA). Journal of asthma and allergy 2020;13:115. doi: 654 https://doi.org/10.2147/JAA.S240044
- 65560. Sol, egrave, r M, Matz J, Townley R, Buhl R, et al. The anti-lgE antibody omalizumab reduces656exacerbations and steroid requirement in allergic asthmatics. The european respiratory journal6572001;18(2):254. doi: https://doi.org/10.1183/09031936.01.00092101
- 61. Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. *Lancet* 2016;388(10039):31-44. doi: 10.1016/s0140-662 6736(16)30307-5 [published Online First: 20160427]
- 663 62. Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et al. Dupilumab in persistent asthma
 664 with elevated eosinophil levels. *New England journal of medicine* 2013;368(26):2455. doi:
 665 <u>https://doi.org/10.1056/NEJMoa1304048</u>
- 666 63. Castro M, Kerwin E, Miller D, Pedinoff A, Sher L, Cardenas P, et al. Efficacy and safety of fevipiprant
 667 in patients with uncontrolled asthma: Two replicate, phase 3, randomised, double-blind,
 668 placebo-controlled trials (ZEAL-1 and ZEAL-2). *EClinicalMedicine* 2021;35 doi:
 669 <u>https://doi.org/10.1016/j.eclinm.2021.100847</u>
- 670 64. Zielen S, Lieb A, De La Motte S, Wagner F, De Monchy J, Fuhr R, et al. Omalizumab protects against
 671 allergen-induced bronchoconstriction in allergic (Immunoglobulin E-mediated) Asthma.
 672 International archives of allergy and immunology 2013;160(1):102. doi:
 673 https://doi.org/10.1159/000339243
- 674 65. Flood-Page P, Swenson C, Faiferman I, Matthews J, Williams M, Brannick L, et al. A study to evaluate 675 safety and efficacy of mepolizumab in patients with moderate persistent asthma. American 676 journal respiratory medicine 2007;176(11):1062. of and critical care doi: 677 https://doi.org/10.1164/rccm.200701-085OC
- 678 66. Gonem S, Berair R, Singapuri A, Hartley R, Laurencin MFM, Bacher G, et al. Fevipiprant, a
 679 prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single680 centre, randomised, double-blind, parallel-group, placebo-controlled trial. *Lancet respiratory*681 medicine 2016;4(9):699. doi: https://doi.org/10.1016/S2213-2600(16)30179-5
- 68267. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. Mepolizumab and683exacerbations of refractory eosinophilic asthma. New England journal of medicine6842009;360(10):973. doi: https://doi.org/10.1056/NEJMoa0808991
- 685 68. Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, et al. Omalizumab in severe
 686 allergic asthma inadequately controlled with standard therapy: a randomized trial. Annals of
 687 internal medicine 2011;154(9):573. doi: <u>https://doi.org/10.7326/0003-4819-154-9-201105030-</u>
 688 00002
- 689 69. Hayashi H, Fukutomi Y, Mitsui C, Kajiwara K, Watai K, Kamide Y, et al. Omalizumab for Aspirin
 690 Hypersensitivity and Leukotriene Overproduction in Aspirin-exacerbated Respiratory Disease. A
 691 Randomized Controlled Trial. American journal of respiratory and critical care medicine
 692 2020;201(12):1488. doi: https://doi.org/10.1164/rccm.201906-12150C
- 69370. Holgate ST, Chuchalin AG, eacute, bert J, ouml, tvall J, et al. Efficacy and safety of a recombinant694anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clinical and695experimental allergy 2004;34(4):632. doi: https://doi.org/10.1111/j.1365-2222.2004.1916.x
- Figure 696 71. Humbert M, Beasley R, Ayres J, Slavin R, eacute, bert J, et al. Benefits of omalizumab as add-on
 therapy in patients with severe persistent asthma who are inadequately controlled despite best

 698
 available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60(3):309. doi:

 699
 https://doi.org/10.1111/j.1398-9995.2004.00772.x

- 700 72. Kopp MV, Hamelmann E, Zielen S, Kamin W, Bergmann KC, Sieder C, et al. Combination of
 701 omalizumab and specific immunotherapy is superior to immunotherapy in patients with
 702 seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. *Clinical and* 703 *experimental allergy* 2009;39(2):271. doi: https://doi.org/10.1111/j.1365-2222.2008.03121.x
- 704 73. Li J, Kang J, Wang C, Yang J, Wang L, Kottakis I, et al. Omalizumab improves quality of life and asthma
 705 control in Chinese patients with moderate to severe asthma: a randomized phase III study.
 706 Allergy, asthma & immunology research 2016;8(4):319. doi:
 707 https://doi.org/10.4168/aair.2016.8.4.319
- 708 74. Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab Efficacy and Safety in
 709 Moderate-to-Severe Uncontrolled Asthma. *New England journal of medicine* 2018;378(26):2486.
 710 doi: <u>https://doi.org/10.1056/NEJMoa1804092</u>
- 711 75. Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, et al. Efficacy and Safety of Dupilumab in
 712 Glucocorticoid-Dependent Severe Asthma. New England journal of medicine 2018;378(26):2475.
 713 doi: <u>https://doi.org/10.1056/NEJMoa1804093</u>
- 714 76. Sabogal P, ntilde, eros YS, Bal SM, van de Pol MA, Dierdorp BS, et al. Anti-IL-5 in Mild Asthma Alters
 715 Rhinovirus-induced Macrophage, B-Cell, and Neutrophil Responses (MATERIAL). A Placebo 716 controlled, Double-Blind Study. *American journal of respiratory and critical care medicine* 717 2019;199(4):508. doi: https://doi.org/10.1164/rccm.201803-04610C
- 77. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment
 in patients with severe eosinophilic asthma. New England journal of medicine
 2014;371(13):1198. doi: <u>https://doi.org/10.1056/NEJMoa1403290</u>
- 721 78. Russell RJ, Chachi L, FitzGerald JM, Backer V, Olivenstein R, Titlestad IL, et al. Effect of tralokinumab,
 722 an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in
 723 uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised,
 724 placebo-controlled phase 2 trial. *Lancet respiratory medicine* 2018;6(7):499. doi:
 725 https://doi.org/10.1016/S2213-2600(18)30201-7
- 726 79. Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, et al. Efficacy of 727 mepolizumab add-on therapy on health-related quality of life and markers of asthma control in 728 severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-729 group, multicentre, phase 3b trial. *Lancet respiratory medicine* 2017;5(5):390. doi: 730 https://doi.org/10.1016/S2213-2600(17)30125-X
- 80. Ohta K, Miyamoto T, Amagasaki T, Yamamoto M. Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma. *Respirology* 2009;14(8):1156-65. doi: http://dx.doi.org/10.1111/j.1440-1843.2009.01633.x
- 73481. Park HS, Kim MK, Imai N, Nakanishi T, Adachi M, Ohta K, et al. A Phase 2a Study of Benralizumab for735Patients with Eosinophilic Asthma in South Korea and Japan. Int Arch Allergy Immunol7362016;169(3):135-45. doi: 10.1159/000444799 [published Online First: 20160421]
- 82. Nowak RM, Parker JM, Silverman RA, Rowe BH, Smithline H, Khan F, et al. A randomized trial of
 benralizumab, an antiinterleukin 5 receptor alpha monoclonal antibody, after acute asthma. *American journal of emergency medicine* 2015;33(1):14. doi:
 <u>https://doi.org/10.1016/j.ajem.2014.09.036</u>
- Rubin AS, Souza-Machado A, Andradre-Lima M, Ferreira F, Honda A, Matozo TM, et al. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a
 Brazilian study (QUALITX). *Journal of asthma* 2012;49(3):288. doi: https://doi.org/10.3109/02770903.2012.660297

- 84. Piper E, Brightling C, Niven R, Oh C, Faggioni R, Poon K, et al. A phase II placebo-controlled study of
 tralokinumab in moderate-to-severe asthma. *The european respiratory journal* 2013;41(2):330.
 doi: <u>https://doi.org/10.1183/09031936.00223411</u>
- 85. Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, et al. Efficacy and safety of
 benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled
 corticosteroids and long-acting &bgr;2-agonists (SIROCCO): a randomised, multicentre, placebocontrolled phase 3 trial. *Lancet (london, england)* 2016;388(10056):2115. doi:
 https://doi.org/10.1016/S0140-6736(16)31324-1
- 75386. Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral glucocorticoid-754sparing effect of mepolizumab in eosinophilic asthma. New England journal of medicine7552014;371(13):1189. doi: https://doi.org/10.1056/NEJMoa1403291
- 87. Kelsen SG, Agache IO, Soong W, Israel E, Chupp GL, Cheung DS, et al. Astegolimab (anti-ST2) efficacy
 and safety in adults with severe asthma: a randomized clinical trial. *Journal of allergy and clinical immunology* 2021;148(3):790. doi: <u>https://doi.org/10.1016/j.jaci.2021.03.044</u>
- 88. Busse W, Spector S, Rosén K, Wang Y, Alpan O. High eosinophil count: a potential biomarker for
 assessing successful omalizumab treatment effects. J Allergy Clin Immunol 2013;132(2):4856.e11. doi: 10.1016/j.jaci.2013.02.032 [published Online First: 20130413]
- 762 89. Casale TB, Chipps BE, Rosén K, Trzaskoma B, Haselkorn T, Omachi TA, et al. Response to omalizumab
 763 using patient enrichment criteria from trials of novel biologics in asthma. *Allergy* 764 2018;73(2):490-97. doi: 10.1111/all.13302 [published Online First: 20170923]
- 90. Hanania NA, Wenzel S, Rosén K, Hsieh HJ, Mosesova S, Choy DF, et al. Exploring the effects of
 omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. *Am J Respir Crit Care Med* 2013;187(8):804-11. doi: 10.1164/rccm.201208-14140C
- Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. *Eur Respir J* 1999;14(4):902-7. doi: 10.1034/j.1399-3003.1999.14d29.x
- 92. Sverrild A, Hansen S, Hvidtfeldt M, Clausson CM, Cozzolino O, Cerps S, et al. The effect of
 tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM). *European Respiratory Journal* 2022;59(1):2101296. doi: https://dx.doi.org/10.1183/13993003.01296-2021
- 93. Tan LD, Nguyen N, Alismail A, Castro M. Management of Uncontrolled Asthma: A Framework for
 Novel and Legacy Biologic Treatments. J Asthma Allergy 2022;15:875-83. doi:
 10.2147/jaa.S369836 [published Online First: 20220629]
- 777 94. Krings JG, McGregor MC, Bacharier LB, Castro M. Biologics for Severe Asthma: Treatment-Specific
 778 Effects Are Important in Choosing a Specific Agent. J Allergy Clin Immunol Pract 2019;7(5):1379 779 92. doi: 10.1016/j.jaip.2019.03.008
- 780 95. Adatia A, Wahab M, Satia I. Is tezepelumab more than just an anti-eosinophil drug? *Eur Respir J* 781 2022;59(1) doi: 10.1183/13993003.01700-2021 [published Online First: 20211231]
- 782

783



A: Exacerbations among patients with eosinophilic asthma

B: Exacerbations among patients with low eosinophils

A: Exacerbations among patients with eosinophilic asthma

B: Exacerbations among patients with low eosinophils

